Jove
Visualize
Contact Us

Related Experiment Videos

[Serum complement composition of myasthenia gravis].

Z S Hao

    Zhonghua Shen Jing Jing Shen Ke Za Zhi = Chinese Journal of Neurology and Psychiatry
    |June 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis.

    Journal of neuroimmunology·1993
    Same author

    Dynamic pupillographic response to positive differential light stimulation in myasthenia gravis.

    Chinese medical journal·1985
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Myasthenia gravis patients show elevated levels of complement components C1-inhibitor (C1-INH) and C5. These findings suggest complement-mediated damage may disrupt neuromuscular endplate receptors in myasthenia gravis.

    Area of Science:

    • Immunology
    • Neurology
    • Complement System

    Context:

    • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
    • The role of the complement system in MG pathogenesis requires further elucidation.

    Purpose:

    • To investigate serum complement levels in patients with myasthenia gravis (MG).
    • To compare complement component levels between MG patients, normal controls, and other neurological disorder cases.

    Summary:

    • Serum levels of complement components C1-inhibitor (C1-INH) and C5 were significantly higher in 54 MG patients compared to 46 normal controls and 42 patients with other neurological disorders (P < 0.01).
    • Elevated C1-INH and C5 levels in MG were independent of clinical type and disease stage.
    • These findings suggest a potential role for complement-mediated immunoreactions in disrupting endplate receptors in MG.

    Related Experiment Videos

    Impact:

    • Provides evidence for complement system involvement in myasthenia gravis pathogenesis.
    • Highlights C1-INH and C5 as potential biomarkers for MG.
    • Suggests complement-mediated mechanisms may contribute to neuromuscular junction dysfunction in MG.